11 Results for "

Indazole derivatives

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "Indazole derivatives" in MCE Product Catalog:

Cat. No.: HY-40294
CAS No.: 271-44-3
Indazole, also called isoindazole, a heterocyclic aromatic organic compound. Its derivatives display a broad variety of biological activities including anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour properties. Indazole and its derivatives can be used for research of cancer, neurological disorders, cardiovascular diseases, gastrointestinal diseases .
loading...
    loading...
Cat. No.: HY-50097
CAS No.: 55289-36-6
3-Bromo-2-methylaniline is an aromatic amine compound and aniline derivative that serves as a starting material and synthetic precursor. 3-Bromo-2-methylaniline acts as a starting material for the synthesis of 4-bromo-1H-indazole and racemic 3,9-dibromo-4,10-dimethyl-6H,12H-5,11-methanodibenzodiazocine. It also serves as a precursor for the regioselective bromination and subsequent deamination to synthesize 1,2-dibromo-3-methylbenzene .
loading...
    loading...
Cat. No.: HY-60298
CAS No.: 79762-54-2
6-Bromo-1H-indazole is an indazole derivative that serves as an intermediate for research related to organic synthesis. 6-Bromo-1H-indazole acts as a building block for the preparation of PI3Kδ inhibitors, and also functions as a synthetic intermediate for the preparation of colchicine site-targeted tubulin polymerization inhibitors[1][2].
loading...
    loading...
Cat. No.: HY-176734
Research Areas:  

Cancer

CZL-S092 is a PLK4 inhibitor with an IC50 value of 0.9 nM and excellent selectivity over other PLK4 family members (PLK1, PLK2, and PLK3). CZL-S092 exhibits anti-neuroblastoma activity in vitro (IMR-32 cells, IC50 = 1.143 μM). CZL-S092 inhibits cell migration and halts the cell cycle and induces apoptosis. CZL-S092 can be used in studies of various cancers including neuroblastoma cancer .
loading...
    loading...
Cat. No.: HY-40294R
CAS No.: 271-44-3
Indazole (Standard) is the analytical standard of Indazole. This product is intended for research and analytical applications. Indazole, also called isoindazole, a heterocyclic aromatic organic compound. Its derivatives display a broad variety of biological activities including anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour properties. Indazole and its derivatives can be used for research of cancer, neurological disorders, cardiovascular diseases, gastrointestinal diseases .
loading...
    loading...
Cat. No.: HY-146366
CAS No.: 2379241-70-8
Target:  

Microtubule/Tubulin

Research Areas:  

Cancer

Tubulin inhibitor 26 (compound 3c) is a potent inhibitor of tubulin. Tubulin inhibitor 26 is an indazole derivative compound. Tubulin inhibitor 26 shows noteworthy low nanomolar potency against HepG2, HCT116, SW620, HT29 and A549 cancer cell lines. Tubulin inhibitor 26 arrests tumor cell in G2/M phase and induced cell apoptosis. Tubulin inhibitor 26 suppresses tumor growth in vivo without affecting the mice body weight .
loading...
    loading...
Cat. No.: HY-118245
CAS No.: 1185282-03-4
Target:  

Cannabinoid Receptor

APP-FUBINACA is a cannabinoid receptor agonist and a derivative of phenylalaninamide-based indazole-3-carboxamide. APP-FUBINACA exhibits neurostimulatory effects .
loading...
    loading...
Cat. No.: HY-100194
CAS No.: 78299-79-3
Target:  

Others

FKK is an indazole derivative and also a novel bronchodilator.
loading...
    loading...
Cat. No.: HY-155362
CAS No.: 2966790-98-5
Purity:  99.96%
Research Areas:  

Cancer

Tubulin polymerization-IN-56 (compound 8l), an indazole derivative, is a potent tubulin polymerization inhibitor through interacting with the colchicine site, resulting in cell cycle arrest and cellular apoptosis. polymerization-IN-56 reduces cell migration and leads to more potent inhibition of tumor growth in vivo .
loading...
    loading...
Cat. No.: HY-179507
Target:  

MDM-2/p53 Apoptosis

Research Areas:  

Cancer

p53 Activator 17 is a p53-Y220C activator. p53 Activator 17 exhibits selective cytotoxicity and pro-apoptotic activity in p53-Y220C mutant cancer cell lines, with minimal effects in wild-type or p53-null cells. p53 Activator 17 induces a mutant-to-wild-type conformational shift in cellular p53-Y220C, accompanied by transcriptional activation of canonical p53 target genes, including BBC3 (PUMA) and MDM2. p53 Activator 17 can be used for the study of hepatocellular carcinoma and breast cancer .
loading...
    loading...
Cat. No.: HY-179506
Target:  

MDM-2/p53 Apoptosis

Research Areas:  

Cancer

P53 Activator 16 (Compound JC16) is a p53 activator. P53 Activator 16 exhibits selective cytotoxicity and pro-apoptotic (apoptosis) activity towards p53-Y220C mutant cancer cells, while having little effect on wild-type or P53-deficient cells. P53 Activator 16 induces the conformational transition of cell p53-Y220C from the mutant form to the wild-type form, accompanied by the transcriptional activation of p53 target genes, without increasing the overall level of p53 protein. P53 Activator 16 can be used for the study of p53 mutant cancers .
loading...
    loading...
  • 1